Zobrazeno 1 - 10
of 39
pro vyhledávání: '"Manoranjenni Chetty"'
Autor:
Paulien Ravenstijn, Manoranjenni Chetty, Pooja Manchandani, Mohamed Elmeliegy, Hisham Qosa, Islam Younis
Publikováno v:
Clinical and Translational Science, Vol 16, Iss 1, Pp 50-61 (2023)
Abstract Despite the liver being the primary site for clearance of xenobiotics utilizing a myriad of mechanisms ranging from cytochrome P450 enzyme pathways, glucuronidation, and biliary excretion, there is a dearth of information available as to how
Externí odkaz:
https://doaj.org/article/b541e2fdeab642659d665e2094055030
Publikováno v:
Clinical and Translational Science, Vol 14, Iss 6, Pp 2111-2116 (2021)
Abstract This review describes the evidence for the potential benefit of vitamin D supplementation in people with respiratory diseases who may have a higher susceptibility to coronavirus disease 2019 (COVID‐19) infection and its consequences. Clini
Externí odkaz:
https://doaj.org/article/380baa1a6b4c44b7be0fd47e5fb10a99
Publikováno v:
Clinical and Translational Science, Vol 14, Iss 5, Pp 1689-1704 (2021)
Abstract An impaired renal function, including acute and chronic kidney disease and end‐stage renal disease, can be the result of aging, certain disease conditions, the use of some medications, or as a result of smoking. In patients with renal impa
Externí odkaz:
https://doaj.org/article/1e55dbd77049413481fa86a0eedb2ec5
Autor:
Laura Oggianu, Alice B. Ke, Manoranjenni Chetty, Rossella Picollo, Vanessa Petrucci, Fabrizio Calisti, Fabio Garofolo, Serena Tongiani
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 9, Iss 2, Pp 77-86 (2020)
There is a paucity of clinical trials for the treatment of pediatric insomnia. This study was designed to predict the doses of trazodone to guide dosing in a clinical trial for pediatric insomnia using physiologically‐based pharmacokinetic (PBPK) m
Externí odkaz:
https://doaj.org/article/3a09e59d97bc467f9ba4516cc214b313
Publikováno v:
Drugs in R&D, Vol 19, Iss 4, Pp 339-350 (2019)
Abstract Background and Objectives The elderly population receives the majority of prescription drugs but are usually excluded from Phase 1 clinical trials. Alternative approaches to estimate increases in toxicity risk or decreases in efficacy are th
Externí odkaz:
https://doaj.org/article/4c76b533f71743939138a02268cfe131
Publikováno v:
Frontiers in Pharmacology, Vol 9 (2018)
Poor metabolisers of CYP2B6 (PM) require a lower dose of efavirenz because of serious adverse reactions resulting from the higher plasma concentrations associated with a standard dose. Treatment discontinuation is a common consequence in patients exp
Externí odkaz:
https://doaj.org/article/3579c1b6d98641969ce65987a7f5e8cd
Autor:
Paulien Ravenstijn, Manoranjenni Chetty, Pooja Manchandani, Mohamed Elmeliegy, Hisham Qosa, Islam Younis
Publikováno v:
Clinical and Translational Science. 16:50-61
Despite the liver being the primary site for clearance of xenobiotics utilizing a myriad of mechanisms ranging from cytochrome P450 enzyme pathways, glucuronidation, and biliary excretion, there is a dearth of information available as to how the seve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5993fc03d96804184b385eda094afc43
https://doi.org/10.1111/cts.13428
https://doi.org/10.1111/cts.13428
Publikováno v:
Clinical Pharmacology & Therapeutics. 109:1203-1211
This review aimed to evaluate the clinical success of clopidogrel dosing based on CYP2C19 genotype and to identify the relevant additional factors that may be useful for consideration by the clinician when dosing individuals with clopidogrel. The res
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::61c8f53d068cb80d791ebae53ece3a51
https://doi.org/10.1002/cpt.2055
https://doi.org/10.1002/cpt.2055
Publikováno v:
European Journal of Clinical Pharmacology. 76:1143-1150
A daily dose of 400 mg of efavirenz (EFV) was recently shown to be ‘not therapeutically inferior’ to a 600-mg daily dose, while providing the added advantage of reduced toxicity risk and cost saving on chronic therapy. However, to our knowledge,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1cc123ef9a3d58b88a86692ff36b6b4f
https://doi.org/10.1007/s00228-020-02890-4
https://doi.org/10.1007/s00228-020-02890-4
Autor:
Fabio Garofolo, Serena Tongiani, Vanessa Petrucci, Fabrizio Calisti, Alice B Ke, Laura Oggianu, Rossella Picollo, Manoranjenni Chetty
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 9, Iss 2, Pp 77-86 (2020)
CPT: Pharmacometrics & Systems Pharmacology
CPT: Pharmacometrics & Systems Pharmacology
There is a paucity of clinical trials for the treatment of pediatric insomnia. This study was designed to predict the doses of trazodone to guide dosing in a clinical trial for pediatric insomnia using physiologically-based pharmacokinetic (PBPK) mod
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c7309e5ef45a4ccab0cc7a5878a21f5
https://doaj.org/article/3a09e59d97bc467f9ba4516cc214b313
https://doaj.org/article/3a09e59d97bc467f9ba4516cc214b313